NCT01001936

Study Evaluating SKI-606 in Subject With Solid Tumors

Phase 1 Does-escalation Study of Oral SKI-606 in Subjects With Advanced Malignant Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 20 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and tolerability of oral SKI-606 (100, 200, 300 or 400 mg) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated dose (MTD) in this subject population. This study will also obtain preliminary information on the pharmacokinetics and antitumor activity of orally administered SKI-606 in subjects with advanced malignant solid tumors

Conditions

• Tumors

Interventions

Type	Name	Description
DRUG	SKI-606

Timeline

• Start date: 2006-02-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2009-10-27
• Last updated: 2009-10-27